Skip to main content
Sarah V. Colonna
( out of 35 reviews )

Sarah V. Colonna, MD

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Hospital North

2K, Plastic and Reconstructive Surgery
Salt Lake City

Veterans Administration Medical Center

Salt Lake City
801-582-1565
  • Dr. Sarah Colonna, MD specializes in caring for women at high risk for breast cancer. She is board certified in internal medicine and medical oncology. Dr. Colonna sees women at risk for breast cancer because of a known genetic mutation, a strong family history of breast cancer or abnormal findings on a breast biopsy. She researches the use of breast MRI as a tool to better quantify breast cancer risk and is involved with longitudinal studies to better understand how the environment can impact on a woman’s risk of breast cancer. Dr. Colonna is also specifically interested in how medical professionals communicate cancer risks to their patients.

    Board Certification

    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Medical Oncology)

    Patient Rating

    4.8 /5
    ( out of 35 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    May 19, 2023
    HUNTSMAN CANCER CENTER

    Dr. Colonna was amazing, she never told me what I should do, but educated me on my options. She gave me HOPE. She is very well educated in BRCA and provides you with wonderful resources and options.

    May 18, 2023
    HUNTSMAN CANCER CENTER

    She basically said how long do you choose to live. Based on that here are your options.

    May 15, 2023
    HUNTSMAN CANCER CENTER

    Very friendly. Interested in me. I didn't feel rushed. Made sure I felt taken care of.

    April 07, 2023
    HUNTSMAN CANCER CENTER

    I found Sarah V. Colonna MD. warn and caring, comprehensive feedback and a lot of positive energy extremely likeable.

    January 26, 2023
    HUNTSMAN CANCER CENTER

    Sarah is fantastic! Really explained options and went into detail about risks/benefits

    January 06, 2023
    HUNTSMAN CANCER CENTER

    Dr. Colonna seemed oblivious to being a full hour late. She didn't introduce herself. At first I couldn't tell if she was the physician. She was unaware of my surgical history, had not reviewed recent imaging, and was not aware of the type of breast cancer in my family (all in my chart). It did not instill confidence that I had to bring these up, each seemed a surprise to her. Point blank, with no guidance, she began asking me, "Do you need X? Do you need Y?" It would have been beneficial to receive evidence based recommendations from her, rather than be asked to make decisions with a dearth of input or advice. I had to inquire about future follow-up. Again, it seemed like planning/explaining this should've been initiated by her. I read my chart after the visit and discovered that it contains inaccuracies, including my breastfeeding status. Overall interactions felt "off" compared to other physicians I've seen at The U of U. This was an expensive appointment. I was disappointed.

    November 20, 2022
    Huntsman Cancer Institute

    Fantastic at answering my questions, didn't feel rushed at all, told me about options and were very positive and upbeat

    October 17, 2022
    HUNTSMAN CANCER CENTER

    Open, honest, provided alternatives for treatment that would help make my daily life better. Took the time with me to help me understand my options. So grateful!

    September 04, 2022
    HUNTSMAN CANCER CENTER

    She was wonderful. I felt she truly understood what I needed and talked through the options and asked me how I would like to proceed. She's very kind, I appreciate her time with me.

  • Dr. Sarah Colonna, MD specializes in caring for women at high risk for breast cancer. She is board certified in internal medicine and medical oncology. Dr. Colonna sees women at risk for breast cancer because of a known genetic mutation, a strong family history of breast cancer or abnormal findings on a breast biopsy. She researches the use of breast MRI as a tool to better quantify breast cancer risk and is involved with longitudinal studies to better understand how the environment can impact on a woman’s risk of breast cancer. Dr. Colonna is also specifically interested in how medical professionals communicate cancer risks to their patients.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Oncology
    Board Certification
    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Medical Oncology)

    Education history

    Graduate Training Clinical Investigation - University of Utah M.S.
    Hematology/Oncology - University of Utah, Huntsman Cancer Institute Fellow
    Fellowship Hematology/Oncology - Vanderbilt University Fellow
    Internal Medicine - Wake Forest University Resident
    Professional Medical Medicine - East Tennessee State University, Quillen College of Medicine M.D.
    Biology, minor in Religion - Lee University B.S.

    Selected Publications

    Journal Article

    1. Morra A, Schreurs MAC, Andrulis IL, Anton-Culver H, Augustinsson A, Beckmann MW, Behrens S, Bojesen SE, Bolla MK, Brauch H, Broeks A, Buys SS, Camp NJ, Castelao JE, Cessna MH, Chang-Claude J, Chung WK, NBCS Collaborators, Colonna SV, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Dennis J, Devilee P, Drk T, Dunning AM, Dwek M, Easton DF, Eccles DM, Eriksson M, Evans DG, Fasching PA, Fehm TN, Figueroa JD, Flyger H, Gabrielson M, Gago-Dominguez M, Garca-Closas M, Garca-Senz JA, Genkinger J, Grassmann F, Gndert M, Hahnen E, Haiman CA, Hamann U, Harrington PA, Hartikainen JM, Hoppe R, Hopper JL, Houlston RS, Howell A, ABCTB Investigators, kConFab Investigators, Jakubowska A, Janni W, Jernstrm H, John EM, Johnson N, Jones ME, Kristensen VN, Kurian AW, Lambrechts D, Le Marchand L, Lindblom A, Lubiski J, Lux MP, Mannermaa A, Mavroudis D, Mulligan AM, Muranen TA, Nevanlinna H, Nevelsteen I, Neven P, Newman WG, Obi N, Offit K, Olshan AF, Park-Simon TW, Patel AV, Peterlongo P, Phillips KA, Plaseska-Karanfilska D, Polley EC, Presneau N, Pylks K, Rack B, Radice P, Rashid MU, Rhenius V, Robson M, Romero A, Saloustros E, Sawyer EJ, Schmutzler RK, Schuetze S, Scott C, Shah M, Smichkoska S, Southey MC, Tapper WJ, Teras LR, Tollenaar RAEM, Tomczyk K, Tomlinson I, Troester MA, Vachon CM, van Veen EM, Wang Q, Wendt C, Wildiers H, Winqvist R, Ziogas A, Hall P, Pharoah PDP, Adank MA, Hollestelle A, Schmidt MK, Hooning MJ (2023). Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival. Cancer Med, 12(15), 16142-16162. (Read full article)
    2. Kast K, John EM, Hopper JL, Andrieu N, Nogus C, Mouret-Fourme E, Lasset C, Fricker JP, Berthet P, Mari V, Salle L, Schmidt MK, Ausems MGEM, Garcia EBG, van de Beek I, Wevers MR, Evans DG, Tischkowitz M, Lalloo F, Cook J, Izatt L, Tripathi V, Snape K, Musgrave H, Sharif S, Murray J, EMBRACE Collaborators, Colonna SV, Andrulis IL, Daly MB, Southey MC, de la Hoya M, Osorio A, Foretova L, Berkova D, Gerdes AM, Olah E, Jakubowska A, Singer CF, Tan Y, Augustinsson A, Rantala J, Simard J, Schmutzler RK, Milne RL, Phillips KA, Terry MB, Goldgar D, van Leeuwen FE, Mooij TM, Antoniou AC, Easton DF, Rookus MA, Engel C (2023). Associations of height, body mass index, and weight gain with breast cancer risk in carriers of a pathogenic variant in BRCA1 or BRCA2: the BRCA1 and BRCA2 Cohort Consortium. Breast Cancer Res, 25(1), 72. (Read full article)
    3. Mueller SH, Lai AG, Valkovskaya M, Michailidou K, Bolla MK, Wang Q, Dennis J, Lush M, Abu-Ful Z, Ahearn TU, Andrulis IL, Anton-Culver H, Antonenkova NN, Arndt V, Aronson KJ, Augustinsson A, Baert T, Freeman LEB, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Blomqvist C, Bogdanova NV, Bojesen SE, Bonanni B, Brenner H, Brucker SY, Buys SS, Castelao JE, Chan TL, Chang-Claude J, Chanock SJ, Choi JY, Chung WK, NBCS Collaborators, Colonna SV, CTS Consortium, Cornelissen S, Couch FJ, Czene K, Daly MB, Devilee P, Drk T, Dossus L, Dwek M, Eccles DM, Ekici AB, Eliassen AH, Engel C, Evans DG, Fasching PA, Fletcher O, Flyger H, Gago-Dominguez M, Gao YT, Garca-Closas M, Garca-Senz JA, Genkinger J, Gentry-Maharaj A, Grassmann F, Gunel P, Gndert M, Haeberle L, Hahnen E, Haiman CA, Hkansson N, Hall P, Harkness EF, Harrington PA, Hartikainen JM, Hartman M, Hein A, Ho WK, Hooning MJ, Hoppe R, Hopper JL, Houlston RS, Howell A, Hunter DJ, Huo D, ABCTB Investigators, Ito H, Iwasaki M, Jakubowska A, Janni W, John EM, Jones ME, Jung A, Kaaks R, Kang D, Khusnutdinova EK, Kim SW, Kitahara CM, Koutros S, Kraft P, Kristensen VN, Kubelka-Sabit K, Kurian AW, Kwong A, Lacey JV, Lambrechts D, Le Marchand L, Li J, Linet M, Lo WY, Long J, Lophatananon A, Mannermaa A, Manoochehri M, Margolin S, Matsuo K, Mavroudis D, Menon U, Muir K, Murphy RA, Nevanlinna H, Newman WG, Niederacher D, OBrien KM, Obi N, Offit K, Olopade OI, Olshan AF, Olsson H, Park SK, Patel AV, Patel A, Perou CM, Peto J, Pharoah PDP, Plaseska-Karanfilska D, Presneau N, Rack B, Radice P, Ramachandran D, Rashid MU, Rennert G, Romero A, Ruddy KJ, Ruebner M, Saloustros E, Sandler DP, Sawyer EJ, Schmidt MK, Schmutzler RK, Schneider MO, Scott C, Shah M, Sharma P, Shen CY, Shu XO, Simard J, Surowy H, Tamimi RM, Tapper WJ, Taylor JA, Teo SH, Teras LR, Toland AE, Tollenaar RAEM, Torres D, Torres-Meja G, Troester MA, Truong T, Vachon CM, Vijai J, Weinberg CR, Wendt C, Winqvist R, Wolk A, Wu AH, Yamaji T, Yang XR, Yu JC, Zheng W, Ziogas A, Ziv E, Dunning AM, Easton DF, Hemingway H, Hamann U, Kuchenbaecker KB (2023). Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry. Genome Med, 15(1), 7. (Read full article)
    4. Li S, Silvestri V, Leslie G, Rebbeck TR, Neuhausen SL, Hopper JL, Nielsen HR, Lee A, Yang X, McGuffog L, Parsons MT, Andrulis IL, Arnold N, Belotti M, Borg, Buecher B, Buys SS, Caputo SM, Chung WK, Colas C, Colonna SV, Cook J, Daly MB, de la Hoya M, de Pauw A, Delhomelle H, Eason J, Engel C, Evans DG, Faust U, Fehm TN, Fostira F, Fountzilas G, Frone M, Garcia-Barberan V, Garre P, Gauthier-Villars M, Gehrig A, Glendon G, Goldgar DE, Golmard L, Greene MH, Hahnen E, Hamann U, Hanson H, Hassan T, Hentschel J, Horvath J, Izatt L, Janavicius R, Jiao Y, John EM, Karlan BY, Kim SW, Konstantopoulou I, Kwong A, Laug A, Lee JW, Lesueur F, Mebirouk N, Meindl A, Mouret-Fourme E, Musgrave H, Ngeow Yuen Yie J, Niederacher D, Park SK, Pedersen IS, Ramser J, Ramus SJ, Rantala J, Rashid MU, Reichl F, Ritter J, Rump A, Santamaria M, Saule C, Schmidt G, Schmutzler RK, Senter L, Shariff S, Singer CF, Southey MC, Stoppa-Lyonnet D, Sutter C, Tan Y, Teo SH, Terry MB, Thomassen M, Tischkowitz M, Toland AE, Torres D, Vega A, Wagner SA, Wang-Gohrke S, Wappenschmidt B, Weber BHF, Yannoukakos D, Spurdle AB, Easton DF, Chenevix-Trench G, Ottini L, Antoniou AC (2022). Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants. J Clin Oncol, JCO2102112. (Read full article)
    5. Morra A, Escala-Garcia M, Beesley J, Keeman R, Canisius S, Ahearn TU, Andrulis IL, Anton-Culver H, Arndt V, Auer PL, Augustinsson A, Beane Freeman LE, Becher H, Beckmann MW, Behrens S, Bojesen SE, Bolla MK, Brenner H, Brning T, Buys SS, Caan B, Campa D, Canzian F, Castelao JE, Chang-Claude J, Chanock SJ, Cheng TD, Clarke CL, NBCS Collaborators, Colonna SV, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Dennis J, Drk T, Dossus L, Dunning AM, Dwek M, Eccles DM, Ekici AB, Eliassen AH, Eriksson M, Evans DG, Fasching PA, Flyger H, Fritschi L, Gago-Dominguez M, Garca-Senz JA, Giles GG, Grip M, Gunel P, Gndert M, Hahnen E, Haiman CA, Hkansson N, Hall P, Hamann U, Hart SN, Hartikainen JM, Hartmann A, He W, Hooning MJ, Hoppe R, Hopper JL, Howell A, Hunter DJ, ABCTB Investigators, kConFab Investigators, Jager A, Jakubowska A, Janni W, John EM, Jung AY, Kaaks R, Keupers M, Kitahara CM, Koutros S, Kraft P, Kristensen VN, Kurian AW, Lacey JV, Lambrechts D, Le Marchand L, Lindblom A, Linet M, Luben RN, Lubiski J, Lush M, Mannermaa A, Manoochehri M, Margolin S, Martens JWM, Martinez ME, Mavroudis D, Michailidou K, Milne RL, Mulligan AM, Muranen TA, Nevanlinna H, Newman WG, Nielsen SF, Nordestgaard BG, Olshan AF, Olsson H, Orr N, Park-Simon TW, Patel AV, Peissel B, Peterlongo P, Plaseska-Karanfilska D, Prajzendanc K, Prentice R, Presneau N, Rack B, Rennert G, Rennert HS, Rhenius V, Romero A, Roylance R, Ruebner M, Saloustros E, Sawyer EJ, Schmutzler RK, Schneeweiss A, Scott C, Shah M, Smichkoska S, Southey MC, Stone J, Surowy H, Swerdlow AJ, Tamimi RM, Tapper WJ, Teras LR, Terry MB, Tollenaar RAEM, Tomlinson I, Troester MA, Truong T, Vachon CM, Wang Q, Hurson AN, Winqvist R, Wolk A, Ziogas A, Brauch H, Garca-Closas M, Pharoah PDP, Easton DF, Chenevix-Trench G, Schmidt MK (2021). Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. Breast Cancer Res, 23(1), 86. (Read full article)
    6. Kaphingst KA, Kohlmann W, Chambers RL, Goodman MS, Bradshaw R, Chan PA, Chavez-Yenter D, Colonna SV, Espinel WF, Everett JN, Gammon A, Goldberg ER, Gonzalez J, Hagerty KJ, Hess R, Kehoe K, Kessler C, Kimball KE, Loomis S, Martinez TR, Monahan R, Schiffman JD, Temares D, Tobik K, Wetter DW, Mann DM, Kawamoto K, Del Fiol G, Buys SS, Ginsburg O, BRIDGE research team (2021). Comparing models of delivery for cancer genetics services among patients receiving primary care who meet criteria for genetic evaluation in two healthcare systems: BRIDGE randomized controlled trial. BMC Health Serv Res, 21(1), 542. (Read full article)
    7. Baron K, Moser JC, Patel S, Grossmann KF, Colonna SV, Hyngstrom JR (2020). Comparative effectiveness of second-line ipilimumab vs. nivolumab in combination with ipilimumab in patients with advanced melanoma who received frontline anti-PD-1 antibodies. J Oncol Pharm Pract, 27(3), 555-559. (Read full article)
    8. Choi YH, Terry MB, Daly MB, MacInnis RJ, Hopper JL, Colonna S, Buys SS, Andrulis IL, John EM, Kurian AW, Briollais L (2022). Association of Risk-Reducing Salpingo-Oophorectomy With Breast Cancer Risk in Women With BRCA1 and BRCA2 Pathogenic Variants. JAMA Oncol, 7(4), 585-592. (Read full article)
    9. Watt GP, Sung J, Morris EA, Buys SS, Bradbury AR, Brooks JD, Conant EF, Weinstein SP, Kontos D, Woods M, Colonna SV, Liang X, Stein MA, Pike MC, Bernstein JL (2020). Association of breast cancer with MRI background parenchymal enhancement: the IMAGINE case-control study. Breast Cancer Res, 22(1), 138. (Read full article)
    10. Knight JA, Kehm RD, Schwartz L, Frost CJ, Chung WK, Colonna S, Keegan THM, Goldberg M, Houghton LC, Hanna D, Glendon G, Daly MB, Buys SS, Andrulis IL, John EM, Bradbury AR, Terry MB (2020). Pre-Pubertal Internalizing Symptoms and Timing of Puberty Onset in Girls. Am J Epidemiol. (Read full article)
    11. Sutherland N, Espinel W, Grotzke M, Colonna S (2020). Unanswered Questions: Hereditary breast and gynecological cancer risk assessment in transgender adolescents and young adults. J Genet Couns, 29(4), 625-633. (Read full article)
    12. Silvestri V, Leslie G, Barnes DR, CIMBA Group, Agnarsson BA, Aittomki K, Alducci E, Andrulis IL, Barkardottir RB, Barroso A, Barrowdale D, Benitez J, Bonanni B, Borg A, Buys SS, Calds T, Caligo MA, Capalbo C, Campbell I, Chung WK, Claes KBM, Colonna SV, Cortesi L, Couch FJ, de la Hoya M, Diez O, Ding YC, Domchek S, Easton DF, Ejlertsen B, Engel C, Evans DG, Feliubadal L, Foretova L, Fostira F, Gczi L, Gerdes AM, Glendon G, Godwin AK, Goldgar DE, Hahnen E, Hogervorst FBL, Hopper JL, Hulick PJ, Isaacs C, Izquierdo A, James PA, Janavicius R, Jensen UB, John EM, Joseph V, Konstantopoulou I, Kurian AW, Kwong A, Landucci E, Lesueur F, Loud JT, Machackova E, Mai PL, Majidzadeh-A K, Manoukian S, Montagna M, Moserle L, Mulligan AM, Nathanson KL, Nevanlinna H, Ngeow J, Nikitina-Zake L, Offit K, Olah E, Olopade OI, Osorio A, Papi L, Park SK, Pedersen IS, Perez-Segura P, Petersen AH, Pinto P, Porfirio B, Pujana MA, Radice P, Rantala J, Rashid MU, Rosenzweig B, Rossing M, Santamaria M, Schmutzler RK, Senter L, Simard J, Singer CF, Solano AR, Southey MC, Steele L, Steinsnyder Z, Stoppa-Lyonnet D, Tan YY, Teixeira MR, Teo SH, Terry MB, Thomassen M, Toland AE, Torres-Esquius S, Tung N, van Asperen CJ, Vega A, Viel A, Vierstraete J, Wappenschmidt B, Weitzel JN, Wieme G, Yoon SY, Zorn KK, McGuffog L, Parsons MT, Hamann U, Greene MH, Kirk JA, Neuhausen SL, Rebbeck TR, Tischkowitz M, Chenevix-Trench G, Antoniou AC, Friedman E, Ottini L (2020). Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). JAMA Oncol, 6(8), 1218-1230. (Read full article)
    13. Moser JC, Wei G, Colonna SV, Grossmann KF, Patel S, Hyngstrom JR (2020). Comparative-effectiveness of pembrolizumab vs. nivolumab for patients with metastatic melanoma. Acta Oncol, 59(4), 434-437. (Read full article)
    14. Greenberg S, Slager S, Neil BO, Cooney K, Maughan B, Stopa N, Venne V, Zickmund S, Colonna S (2020). What men want: Qualitative analysis of what men with prostate cancer (PCa) want to learn regarding genetic referral, counseling, and testing. Prostate, 80(5), 441-450. (Read full article)
    15. Moser JC, Chen D, Hu-Lieskovan S, Grossmann KF, Patel S, Colonna SV, Ying J, Hyngstrom JR (2019). Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab. Cancer Med, 8(18), 7637-7643. (Read full article)
    16. Colonna S, Sweetenham J, Burgon TB, Buys SS, Lynch R, Au T, Johnson E, Kubal T, Paculdo D, Acelajado MC, Peabody JW (2018). A Better Pathway? Building Consensus and Engaging Providers with Feedback to Improve and Standardize Cancer Care. Clin Breast Cancer, 19(2), e376-e384. (Read full article)
    17. Colonna S, Curtin K, Johnson E, Kohlmann W, Wright J, Kirchhoff A, Tavtigian S, Schiffman J (2019). Family History of Breast Cancer Associated with Breast Cancer in Survivors of Hodgkin Lymphoma. Int J Cancer Clin Res, 6(1). (Read full article)
    18. Carmichael H, Matsen C, Freer P, Kohlmann W, Stein M, Buys SS, Colonna S (2017). Breast cancer screening of pregnant and breastfeeding women with BRCA mutations. Breast Cancer Res Treat, 162(2), 225-230. (Read full article)
    19. Carmicheal H, Matsen C, Freer P, Kohlmann W, Stein M, Buys SS, Colonna S, MD (2017). Breast cancer screening of pregnant and breastfeeding women with BRCA mutations. doi: 10.1007/s10549-017-4122-y. Review. PubMed PMID: 28138892. Breast Cancer Res Treat, 162(2), 225-230.
    20. Colonna SV, Higgins AK, Alvarez J, Saville BR, Lawrence J, Abramson VG (2015). Analysis of Risk of Recurrence by Subtype in ≤ 1-cm Breast Tumors. Clin Breast Cancer, 16(3), 223-31. (Read full article)
    21. Colonna S, Halwani A, Ying J, Buys S, Sweeney C (2015). Women with breast cancer in the Veterans Health Administration: demographics, breast cancer characteristics, and trends. Med Care, 53(4 Suppl 1), S149-55. (Read full article)
    22. Colonna SV, Douglas Case L, Lawrence JA (2011). A retrospective review of the metabolic syndrome in women diagnosed with breast cancer and correlation with estrogen receptor. Breast Cancer Res Treat, 131(1), 325-31. (Read full article)

    Book Chapter

    1. Colonna SV, Gammon A (2016). Management of the Patient with a Genetic Predisposition for Breast Cancer. In Dr. Ismail Jatoi and Dr. Achim Rody (Eds.), Management of Breast Diseases (Second Edition).
    2. Colonna SV, Werner T (2015). Breast cancer bone metastases. In Lor Randall (Ed.), Metastatic Bone Disease: Essentials for the Orthopedic Surgeon. Springer International.
    3. Colonna SV, Goff L, Berlin J (2013). Biliary Tree Cancer. In Decision Support in Medicine: Oncology.

    Editorial

    1. Kohlmann W, Champine M, Colonna SV (May 31, 2015). Communicating Genetic Test Results to Patients and Their Families. ASCO Daily News.

    Abstract

    1. Colonna SV, Curtin K, Kohlmann W, Wright J, Tavtigian S, Schiffman J (2015). Family history of breast cancer in Hodgkin disease and future risk of breast cancer. [Abstract]. J Clin Oncol, 33(suppl), abstr 1522.
    2. Halwani A, Colonna SV, Ying J, Buys S, Sweeney C (2014). Geographic distribution of rural-urban status of women with breast cancer in the Veterans Health Administration using two schemes: Rural Urban Continuum and Rural Urban Commuting Areas [Abstract]. Association of VA Hematology/Oncology.
    3. Colonna SV, Halwani A, Ying J, Sweeney C, Buys S (2014). Breast cancer treatment among rural and urban veterans at the Veterans Health Administration: also presented as a poster. [Abstract]. Association of VA Hematology/Oncology.
    4. Udomaksorn S, Stenehjem D, Welch BM, Cheng Y, Anderson L, Colonna S, Neumayer L, Brixner D (2013). Evaluation of variable relevance and accessibility to support personalized medicine in breast cancer [Abstract]. ISPOR 16th Annual European Congress, Dublin, Ireland.
    5. Colonna SV, Higgins AK, Alvarez J, Saville B, Lawrence JA, Abramson VA (2013). Analysis of recurrence risk by subtype in <1cm breast tumors [Abstract]. Journal of Clinical Oncology.
    6. Colonna SV, Douglas Case L, Lawrence JA (2009). Correlation of the Metabolic Syndrome with Estrogen Receptor Negative Breast Cancer in a Retrospective Review [Abstract].
  • News & Podcasts